Fistulizing Crohn's disease

被引：10
|
作者：
Felley, C
Mottet, C
Juillerat, P
Froehlich, F
Burnand, B
Vader, JP
Michetti, P
Gonvers, JJ
机构：
[1] Univ Lausanne, Med Ctr, Div Gastroenterol & Hepatol, CH-1011 Lausanne, Switzerland
[2] Univ Basel, Gastrointestinal Dept, Basel, Switzerland
[3] Univ Lausanne, Inst Social & Prevent Med, Lausanne, Switzerland
来源：
DIGESTION | 2005年 / 71卷 / 01期
关键词：
Crohn's disease; fistula; antibiotics; azathioprine; infliximab; methotrexate; cyclosporine; tacrolimus; internal fistulas; surgery;
D O I：
10.1159/000083868
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Fistulas are common in Crohn's disease. A population-based study has shown a cumulative risk of 33% after 10 years and 50% after 20 years. Perianal fistulas were the most common (54%). Medical therapy is the main option for perianal fistula once abscesses, if present, have been drained, and should include antibiotics ( both ciprofloxacin and metronidazole) and immunomodulators. Infliximab should be reserved for refractory patients. Surgery is often necessary for internal fistulas. Copyright (C) 2005 S. Karger AG, Basel.
引用
收藏
页码：26 / 28
页数：3
相关论文
共 50 条
  • [1] Fistulizing Crohn's disease
    Felley, Christian
    Mottet, Christian
    Juillerat, Pascal
    Pittet, Valerie
    Froehlich, Florian
    Vader, John-Paul
    Michetti, Pierre
    Gonvers, Jean-Jacques
    DIGESTION, 2007, 76 (02) : 109 - 112
  • [2] Pharmacological treatment of fistulizing Crohn's disease
    Gisbert, JP
    Gomollón, F
    Maté, J
    Pajares, JM
    MEDICINA CLINICA, 2001, 116 (17): : 664 - 671
  • [3] Fistulizing Crohn's disease: Diagnosis and management
    Gecse, Krisztina
    Khanna, Reena
    Stoker, Jaap
    Jenkins, John T.
    Gabe, Simon
    Hahnloser, Dieter
    D'Haens, Geert
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2013, 1 (03) : 206 - 213
  • [4] Diagnosis and management of fistulizing Crohn's disease
    Nielsen, Ole Haagen
    Rogler, Gerhard
    Hahnloser, Dieter
    Thomsen, Ole Ostergaard
    NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY, 2009, 6 (02): : 92 - 106
  • [5] The management of fistulizing oral Crohn's disease with infliximab
    Staines, K. S.
    Green, R.
    Felix, D. H.
    JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2007, 36 (07) : 444 - 446
  • [6] Patient-reported Outcome Measures in Perianal Fistulizing Crohn's Disease
    Freitas Queiroz, Natalia Sousa
    Garcia, Karoline Soares
    Miranda, Eron Fabio
    Kotze, Paulo Gustavo
    REVIEWS ON RECENT CLINICAL TRIALS, 2022, 17 (03) : 143 - 155
  • [7] Prognostic factors for the efficacy of infliximab in patients with luminal fistulizing Crohn's disease
    Ma, Ye
    Zhang, Runfeng
    Liu, Wei
    Sun, Yinghao
    Li, Jingnan
    Yang, Hong
    Lv, Hong
    Li, Yue
    Tan, Bei
    Sun, Xiyu
    Qian, Jiaming
    Li, Ji
    BMC GASTROENTEROLOGY, 2023, 23 (01)
  • [8] Management of Perianal Fistulizing Crohn's Disease
    Singh, Arshdeep
    Midha, Vandana
    Kochhar, Gursimran Singh
    Shen, Bo
    Sood, Ajit
    INFLAMMATORY BOWEL DISEASES, 2023, 30 (09) : 1579 - 1603
  • [9] Treatment of Fibrostenotic and Fistulizing Crohn's Disease
    Schoepfer, Alain M.
    Safroneeva, Ekaterina
    Vavricka, Stephan R.
    Peyrin-Biroulet, Laurent
    Mottet, Christian
    DIGESTION, 2012, 86 : 23 - 27
  • [10] Predictors of response to infliximab in patients with fistulizing Crohn's disease
    Luna-Chadid, M
    Calle, JLP
    Mendoza, JL
    Vera, MI
    Bermejo, AF
    Sánchez, F
    San Román, AL
    Froilán, C
    González-Lara, V
    García-Paredes, J
    Fernández-Blanco, I
    Abreu, L
    Casis, B
    Herruzo, JAS
    Gisbert, JP
    Maté-Jiménez, J
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2004, 96 (06) : 379 - 381
12345